Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530698 | 0.89 | HSD17B10 (0.47) | PTGS2PTGS1ALDH1A1TSHRTDP1 | |
| SCHEMBL14112766 | 0.87 | ALOX15 (0.44) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL7968046 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1ALDH1A1TSHRTDP1 | |
| SCHEMBL12678876 | 0.86 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1TSHRTDP1 | |
| SCHEMBL1730807 | 0.86 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1TSHRTDP1 | |
| SCHEMBL28939024 | 0.83 | PTGDR2 (0.37) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL1542335 | 0.82 | PTGS2 (0.38) | PTGS2PTGS1ALDH1A1TSHRTDP1 | |
| SCHEMBL1764339 | 0.81 | PTGS2 (0.37) | PTGS2PTGS1ALDH1A1TSHRTDP1 | |
| SCHEMBL1542282 | 0.81 | ERN1 (0.47) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL6832664 | 0.81 | PTGS2 (0.37) | PTGS2PTGS1ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113603572-B | Preparation method of 2, 6-di-tert-butyl-4-bromoanisole | 黑龙江立科新材料有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-113603572-A | Preparation method of 2, 6-di-tert-butyl-4-bromoanisole | 黑龙江立科新材料有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-115340503-B | Synthesis method and application of chiral semicorrinoid compound | 四川师范大学 | 2024-12-24 | — | — | CN | disclosed |
| US-20240209127-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TOTALENERGIES ONETECH BELGIUM (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240209127-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TOTALENERGIES ONETECH BELGIUM (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240209127-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TOTALENERGIES ONETECH BELGIUM (BE) | 2024-06-27 | — | — | US | disclosed |
| EP-4347667-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TotalEnergies OneTech Belgium (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-113603572-B | Preparation method of 2, 6-di-tert-butyl-4-bromoanisole | 黑龙江立科新材料有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113603572-B | Preparation method of 2, 6-di-tert-butyl-4-bromoanisole | 黑龙江立科新材料有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113603572-B | Preparation method of 2, 6-di-tert-butyl-4-bromoanisole | 黑龙江立科新材料有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117396523-A | Novel metallocene catalysts and their use | 道达尔能源一技术比利时公司 | 2024-01-12 | — | — | CN | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7135582-B2 | Transition metal complex having diphosphine compound as ligand | TAKEDA PHARMACEUTIACAL COMPANY LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060094887-A1 | Transition metal complex having diphosphine compound as ligand | SPERA PHARMA, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1568701-A1 | TRANSITION METAL COMPLEX HAVING DIPHOSPHINE COMPLEX AS LIGAND | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| EP-0540108-B1 | Catalyst composition | SHELL INT RESEARCH (NL) | 1996-01-03 | — | — | EP | disclosed |
| US-5279999-A | Catalyst composition | SHELL OIL COMPANY (US) | 1994-01-18 | — | — | US | disclosed |
| EP-0540108-A1 | Catalyst composition | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094887-A1 | Transition metal complex having diphosphine compound as ligand | TERT, AP1M1, AP2M1 | PTGS2 4163/4885PTGS1 4316/4885ALDH1A1 4339/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | PTGS2 3590/4885PTGS1 3254/4885ALDH1A1 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.